Research programme: human monoclonal antibodies - XTL Biopharmaceuticals/Dyax

Drug Profile

Research programme: human monoclonal antibodies - XTL Biopharmaceuticals/Dyax

Alternative Names: Human monoclonal antibodies research programme - XTL Biopharmaceuticals/Dyax; Onco-TrimeraXTL

Latest Information Update: 03 Oct 2002

Price : $50

At a glance

  • Originator Dyax; XTL Biopharmaceuticals
  • Developer Dyax Corp.; XTL Biopharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Mycoses

Most Recent Events

  • 03 Oct 2002 Discontinued - Preclinical for Mycoses in USA (unspecified route)
  • 03 Oct 2002 Discontinued - Preclinical for Mycoses in Israel (unspecified route)
  • 03 Oct 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top